Breast cancer and pregnancy: Current concepts in diagnosis and treatment

Oncologist

Volumn 15, Issue 12, 2010, Pages 1238-1247

  Litton, Jennifer K ^a   Theriault, Richard L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Birth defects; Breast cancer; Chemotherapy; Pregnancy; Prognosis; Teratogenicity

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; LORAZEPAM; METHOTREXATE; ONDANSETRON; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

AMBIGUOUS GENITALIA; ANAPHYLAXIS; ANHYDRAMNIOS; AUTOIMMUNE DISEASE; BIRTH DEFECT; BREAST CANCER; BREAST FEEDING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CAPILLARY LEAK SYNDROME; CELLULITIS; CONSTIPATION; CONTINUOUS INFUSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; ECHOGRAPHY; ENTEROCOLITIS; FETUS DISEASE; GOLDENHAR SYNDROME; HETEROZYGOSITY; HUMAN; HYPERBILIRUBINEMIA; INTERPERSONAL COMMUNICATION; INTRAUTERINE GROWTH RETARDATION; KIDNEY DYSFUNCTION; LACTATION; LUNG DISEASE; LYMPH NODE BIOPSY; MAMMOGRAPHY; MASTECTOMY; MOUTH ULCER; MULTIPLE ORGAN FAILURE; NAUSEA; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOHYDRAMNIOS; OUTCOME ASSESSMENT; PLACENTA DISORDER; PLACENTA INSUFFICIENCY; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; SECOND TRIMESTER PREGNANCY; SEPSIS; SPONTANEOUS ABORTION; TACHYCARDIA; TERATOGENICITY; THERAPY DELAY; THIRD TRIMESTER PREGNANCY; TUMOR BIOPSY; VAGINA BLEEDING;

BREAST NEOPLASMS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 78650982369     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0262     Document Type: Review

References (78)

1. Smith LH, Dalrymple JL, Leiserowitz GS et al. Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol 2001;184:1504-1512; discussion 1512-1513.
2. Altekruse SF, Kosary CL, Krapcho M et al., eds. SEER Cancer Statistics Review 1975-2007. Bethesda, MD: National Cancer Institute, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Available at http://seer.cancer.gov/csr/1975_2007/, accessed November 5, 2010.
3. Stensheim H, Moller B, van Dijk T et al. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: A registry-based cohort study. J Clin Oncol 2009;27:45-51.
4. Martin JA, Kochanek KD, Strobino DM et al. Annual summary of vital statistics-2003. Pediatrics 2005;115:619-634.
5. Andersson TM, Johansson AL, Hsieh CC et al. Increasing incidence of pregnancy-associated breast cancer in Sweden. Obstet Gynecol 2009;114: 568-572. DOI: 10.1097/AOG. 0b013e3181b19154.
6. Ishida T, Yokoe T, Kasmu F et al. Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: Analysis of case-control study in Japan. Jpn J Cancer Res 1992;83:1143-1149.
7. Loibl S, von Minckwitz G, Gwyn K et al. Breast carcinoma during pregnancy. Cancer 2006;106:237-246.
8. Nicklas AH, Baker ME. Imaging strategies in the pregnant breast cancer patient. Semin Oncol 2000;27:623-632.
9. Brent RL. The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: Counseling the pregnant and nonpregnant patient about these risks. Semin Oncol 1989;16:347-368.
10. Mazonakis M, Varveris H, Damilakis J et al. Radiation dose to conceptus resulting from tangential breast irradiation. Int J Radiat Oncol Biol Phys 2003;55:386-391.
11. Yang WT, Dryden MJ, Gwyn K et al. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology 2006;239:52-60.
12. Novak Z, Thurmond AS, Ross PL et al. Gadolinium DTPA transplacental transfer and distribution in fetal tissue in rabbits. Invest Radiol 1993;28: 828-830.
13. DeSantis M, Lucchese A, DeCarolis S et al. Metastatic breast cancer in pregnancy: First case of chemotherapy with docetaxel. Eur J Cancer Care 2000;9:235-237.
14. Birchard KR, Brown MA, Hyslop WB et al. MRI of acute abdominal and pelvic pain in pregnant patients. Am J Roentgenol 2005;184:452-458.
15. Webb JA, Thomsen HS, Morcos SK; Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 2005;15:1234-1240.
16. Schackmuth EM, Harlow CL, Norton LW. Milk fistula: A complication after core breast biopsy. AJR Am J Roentgenol 1993;161:961-962.
17. Dominici LS, Kuerer HM, Babiera G et al. Wound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis 2010 Jun 1 [Epub ahead of print].
18. Mazze RI, Källén B. Reproductive outcome after anesthesia and operation during pregnancy: A registry study of 5405 cases. J Obstet Gynecol 1989; 161:1178-1185.
19. Duncan PG, Pope WD, Cohen M et al. Fetal risk of anesthesia and surgery during pregnancy. Anesthesiology 1986;64:790-794.
20. Cardonick E, Dougherty R, Grana G et al. Breast cancer during pregnancy: Maternal and fetal outcomes. Cancer J 2010;16:76-82.
21. Keleher A, Wendt R 3rd, Delpassand E et al. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J 2004;10:492-495.
22. Montgomery LL, Thorne AC, Van Zee KJ et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg 2002;95:385-388.
23. Raut CP, Hunt KK, Akins JS et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: Results of a surgical prospective clinical practice protocol. Cancer 2005;104:692-699.
24. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol 1989;16:337-346.
25. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004;5:283-291.
26. Hahn KM, Johnson PH, Gordon N et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006;107:1219-1226.
27. Berry DL, Theriault RL, Holmes FA et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999;17: 855-861.
28. Giacalone P, Laffargue F, Bénos P. Chemotherapy for breast carcinoma during pregnancy A French national survey. Cancer 1999;86:2266-2272.
29. Van Calsteren K, Heyns L, De Smet F et al. Cancer during pregnancy: An analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 2010;28:683-689.
30. Mir O, Berveiller P, Rouzier R et al. Chemotherapy for breast cancer during pregnancy: Is epirubicin safe? Ann Oncol 2008;19:1814-1815.
31. Ring AE, Smith IE, Jones A et al. Chemotherapy for breast cancer during pregnancy: An 18-year experience from five London teaching hospitals. J Clin Oncol 2005;23:4192-4197.
32. Mir O, Berveiller P, Goffinet F et al. Taxanes for breast cancer during pregnancy: A systematic review. Ann Oncol 2010;21:425-426.
33. Anderson GD. Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clin Pharmacokinet 2005;44:989-1008.
34. Lycette JL, Dul CL, Munar M et al. Effect of pregnancy on the pharmacokinetics of paclitaxel: A case report. Clin Breast Cancer 2006;7:342-344.
35. Beale JM, Tuohy J, McDowell SJ. Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am J Obstet Gynecol 2009;201:e13-e14.
36. Shrim A, Garcia-Bournissen F, Maxwell C et al. Trastuzumab treatment for breast cancer during pregnancy. Can Fam Physician 2008;54:31-32.
37. Goodyer MJ, Ismail JR, O'Reilly SP et al. Safety of trastuzumab (Herceptin) during pregnancy: Two case reports. Cases J 2009;2:9329.
38. Fanale MA, Uyei AR, Theriault RL et al. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 2005;6:354-356.
39. Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: Association with reversible anhydramnios. Obstet Gynecol 2005;105:642-643.
40. Waterston AM, Graham J. Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol 2006;24:321-322.
41. Bader AA, Schlembach D, Tamussino KF et al. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 2007;8:79-81.
42. Sekar R, Stone PR. Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol 2007;110:507-510.
43. Witzel ID, Miler V, Harps E et al. Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 2008;19:191-192.
44. Pant S, Landon MB, Blumenfeld M et al. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 2008;26:1567-1569.
45. Kelly H, Graham M, Humes E et al. Delivery of a healthy baby after firsttrimester maternal exposure to lapatinib. Clin Breast Cancer 2006;7:339-341.
46. Clark S. Prophylactic tamoxifen. Lancet 1993;342:168.
47. Cullins SL, Pridjian G, Sutherland CM. Goldenhar's syndrome associated with tamoxifen given to the mother during gestation. JAMA 1994;271: 1905-1906.
48. Cunha GR, Taguchi O, Namikawa R et al. Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. Hum Pathol 1987;18:1132-1143.
49. Isaacs RJ, Hunter W, Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy-case report and literature review. Gynecol Oncol 2001;80:405-408.
50. Tewari K, Bonebrake RG, Asrat T et al. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 1997;350:183.
51. Bilgin K, Yaramis A, Haspolat K et al. A randomized trial of granulocytemacrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001;107:36-41.
52. Schibler KR, Osborne KA, Leung LY et al. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998;102:6-13.
53. Briggs G, Freeman R, Yaffee S. A reference guide to fetal and neonatal risk: Drugs in pregnancy and lactation. Philadelphia: Lippincott Williams & Wilkins, 2008:447, 719-720.
54. Ribeiro G, Jones DA, Jones M. Carcinoma of the breast associated with pregnancy. Br J Surg 1986;73:607-609.
55. Tretli S, Kvalheim G, Thoresen S et al. Survival of breast cancer patients diagnosed during pregnancy or lactation. Br J Cancer 1988;58:382-384.
56. Bonnier P, Romain S, Dilhuydy JM et al. Influence of pregnancy on the outcome of breast cancer: A case-control study. Société Française de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 1997;72: 720-727.
57. Beadle BM, Woodward WA, Middleton LP et al. The impact of pregnancy on breast cancer outcomes in women ≤35 years. Cancer 2009;115:1174-1184.
58. Ezzat A, Raja A, Berry J et al. Impact of pregnancy on non-metastatic breast cancer: A case control study. Clin Oncol 1996;8:367-370.
59. Zemlickis D, Lishner M, Degendorfer P et al. Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol 1992;166:781-787.
60. Lethaby AE, O'Neill MA, Mason BH et al. Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group. Int J Cancer 1996;67:751-755.
61. Murphy C, Mallam D, Stein S et al. Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study. J Clin Oncol 2010;28(15 suppl):1589.
62. Queisser-Luft A, Stolz G, Wiesel A et al. Malformations in newborn: Results based on 30,940 infants and fetuses from the Mainz congenital birth defect monitoring system (1990-1998). Arch Gynecol Obstet 2002;266: 163-167.
63. Avilés A, Neri N. Hematologic malignancies and pregnancy: A final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2001; 2:173-177.
64. Avilés A, Neri N, Nambo MJ. Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann Oncol 2006; 17:286-288.
65. Reynoso EE, Shepherd FA, Messner HA et al. Acute leukemia during pregnancy: The Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol 1987;5:1098-1106.
66. Zoccarato G, Romagnolo C, Ghiotto C et al. High frequency of premature births in concomitant pregnancy and cancer [abstract e12020]. J Clin Oncol 2010;28:e12020.
67. Nugent P, O'Connell TX. Breast cancer and pregnancy. Arch Surg 1985; 120:1221-1224.
68. Clark RM, Chua T. Breast cancer and pregnancy: The ultimate challenge. Clin Oncol (R Coll Radiol) 1989;1:11-18.
69. Deemarsky L, Neishtadt E. Breast cancer and pregnancy. Breast 1981;7:17.
70. JI. Administration of cyclophosphamide during late pregnancy and early lactation: A case report. J Natl Med Assoc 1979;71:165-166.
71. Antoniou AC, Shenton A, Maher ER et al. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2006;8: R72.
72. Andrieu N, Goldgar DE, Easton DF et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 2006;98:535-544.
73. Tryggvadottir L, Olafsdottir EJ, Gudlaugsdottir S et al. BRCA2 mutation carriers, reproductive factors and breast cancer risk. Breast Cancer Res 2003;5:R121-R125.
74. Jernström H, Lerman C, Ghadirian P et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999;354:1846-1850.
75. Cullinane CA, Lubinski J, Neuhausen SL et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 2005;117:988-991.
76. Kotsopoulos J, Lubinski J, Lynch HT et al. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2007;105:221-228.
77. Tryggvadóttir L, Tulinius H, Eyfjord JE et al. Breast cancer risk factors and age at diagnosis: An Icelandic cohort study. Int J Cancer 2002;98:604-608.
78. Jernström H, Lubinski J, Lynch HT et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2004;96:1094-1098.